Drug
AZD6765 clinical trials
Also written AZD6765.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Other names
Studies by the year they started
10 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Studies
Open first, then newest update. How each study uses AZD6765 is read from its arms, and is right about nine times in ten.
Testing it · 10
- NMDA Receptor Modulation for Hyperarousal in PTSDCompletedPhase 1Baylor College of MedicineNCT03166501Written as Lanicemine
- A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive DisorderCompletedPhase 2AstraZenecaNCT01482221Written as AZD6765 iv
- This is a Study to Determine the Antidepressant Effects of AZD6765CompletedPhase 2AstraZenecaNCT00986479Written as AZD6765
- Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female SubjectsCompletedPhase 1AstraZenecaNCT01046630Written as AZD6765
- A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood LevelsCompletedPhase 1AstraZenecaNCT01069822Written as AZD6765
- AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian SubjectsCompletedPhase 1AstraZenecaNCT00785915Written as AZD6765
- A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765TerminatedPhase 1AstraZenecaNCT01130909Written as AZD6765
- AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)WithdrawnPhase 1AstraZenecaNCT00963365Written as AZD6765
- AZD6765 Severe Major Depressive Disorder (MDD) IVCompletedPhase 2AstraZenecaNCT00781742Written as AZD6765
- AZD6765 for Treatment Resistant DepressionCompletedPhase 2AstraZenecaNCT00491686Written as AZD6765